Anti-tumor necrosis factor α: originators < em > versus < /em > biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies
CONCLUSIONS: Real-life data demonstrated a similar safety profile between biosimilars and originators, but a reduced biosimilar retention rate at 24 months. Biosimilars could be considered a valid, safe, and less expensive alternative to originators, allowing access to treatments for a wider patient population.PMID:38115772 | DOI:10.4081/reumatismo.2023.1602 (Source: Reumatismo)
Source: Reumatismo - December 20, 2023 Category: Rheumatology Authors: C Gioia A Picchianti Diamanti R Perricone M S Chimenti A Afeltra L Navarini A Migliore U Massafra V Bruzzese P Scolieri C Meschini M Paroli R Caccavale P Scapato R Scrivo F Conti B Lagan à M Di Franco Source Type: research

Defining a therapeutic range for adalimumab serum concentrations in the management of pediatric noninfectious uveitis, a step towards personalized treatment
The objective of this study was to define a therapeutic range for adalimumab trough levels in... (Source: Pediatric Rheumatology)
Source: Pediatric Rheumatology - December 20, 2023 Category: Rheumatology Authors: Jo L. Dehoorne, Helena Groth, Emma Carl é, Ilse De Schrijver, Celine Sys, Patricia Delbeke, Elke O. Kreps, Thomas Renson and Carolien Bonroy Tags: Research article Source Type: research

Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases
Adv Ther. 2023 Dec 19. doi: 10.1007/s12325-023-02737-1. Online ahead of print.ABSTRACTSB5 is an approved biosimilar of adalimumab, a recombinant monoclonal anti-tumor necrosis factor (TNF) antibody. The approval of SB5 was based on the comparison with reference adalimumab in analytical studies, pharmacokinetic (PK) and immunogenicity assessments, and randomized controlled trials. Efficacy data was primarily obtained in patients with rheumatoid arthritis, and extended to include additional indications such as psoriasis, Crohn's disease, or ulcerative colitis by extrapolation. Following its approval, additional post-marketin...
Source: Adv Data - December 19, 2023 Category: Epidemiology Authors: Jonathan Kay Raymond K Cross Steven R Feldman Younjin Park Stephen B Hanauer Source Type: research

Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases
Adv Ther. 2023 Dec 19. doi: 10.1007/s12325-023-02737-1. Online ahead of print.ABSTRACTSB5 is an approved biosimilar of adalimumab, a recombinant monoclonal anti-tumor necrosis factor (TNF) antibody. The approval of SB5 was based on the comparison with reference adalimumab in analytical studies, pharmacokinetic (PK) and immunogenicity assessments, and randomized controlled trials. Efficacy data was primarily obtained in patients with rheumatoid arthritis, and extended to include additional indications such as psoriasis, Crohn's disease, or ulcerative colitis by extrapolation. Following its approval, additional post-marketin...
Source: Adv Data - December 19, 2023 Category: Epidemiology Authors: Jonathan Kay Raymond K Cross Steven R Feldman Younjin Park Stephen B Hanauer Source Type: research

Structure ‐Based Development of a Canine TNF‐α‐Specific Antibody Using Adalimumab as a Template
This article is protected by copyright. All rights reserved. (Source: Protein Science)
Source: Protein Science - December 19, 2023 Category: Biochemistry Authors: Cheng ‐Chung Lee, Wen‐Chih Kuo, Ya‐Wen Chang, Shu‐Fang Hsu, Chia‐Hung Wu, Ya‐Wen Chen, Jui‐Jen Chang, Andrew H.‐J. Wang Tags: RESEARCH ARTICLE Source Type: research

Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases
AbstractSB5 is an approved biosimilar of adalimumab, a recombinant monoclonal anti-tumor necrosis factor (TNF) antibody. The approval of SB5 was based on the comparison with reference adalimumab in analytical studies, pharmacokinetic (PK) and immunogenicity assessments, and randomized controlled trials. Efficacy data was primarily obtained in patients with rheumatoid arthritis, and extended to include additional indications such as psoriasis, Crohn ’s disease, or ulcerative colitis by extrapolation. Following its approval, additional post-marketing data have been collected comparing SB5 with reference adalimumab. This re...
Source: Advances in Therapy - December 19, 2023 Category: Drugs & Pharmacology Source Type: research

Effectiveness and safety of adalimumab in patients with intestinal Beh çet’s disease: a real-world prospective observational study in South Korea
Intestinal Beh çet’s disease (BD) is characterized by typical gastrointestinal ulcers in patients with BD followed by complications such as bleeding, perforation and fistula. Biologic agents are currently under... (Source: BMC Gastroenterology)
Source: BMC Gastroenterology - December 19, 2023 Category: Gastroenterology Authors: Jongwook Yu, Sung Jae Shin, Yune-Jung Park, Hyung Wook Kim, Bo-In Lee, Byong Duk Ye, Geun-Tae Kim, Sung Kook Kim, Joo Sung Kim, Young-Ho Kim, Seonjeong Jeong and Jae Hee Cheon Tags: Research Source Type: research

Cost Effectiveness of Tofacitinib for the Treatment of Active Ankylosing Spondylitis in Greece
ConclusionsTofacitinib was estimated to be a cost-effective option for the treatment of active ankylosing spondylitis in Greece for both biologic-naive and biologic-experienced patients. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - December 16, 2023 Category: Drugs & Pharmacology Source Type: research

Health-related quality of life of patients with rheumatoid arthritis on tocilizumab, adalimumab, and etanercept in Saudi Arabia: a single-center cross-sectional study
Conclusion: The use of tocilizumab did not seem to result in better QOL among RA patients. Future studies with larger sample sizes and more robust designs should be conducted to confirm or refute these findings. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - December 15, 2023 Category: Drugs & Pharmacology Source Type: research

Adalimumab Effectively Decreases Inflammation Downstream of TNF α Signaling in Synoviocytes from Extended Oligoarticular Juvenile Idiopathic Arthritis
ConclusionsThis data suggests that, after only 24  h, adalimumab is effective at decreasing inflammation that occurs downstream of initial TNFα signaling in extended-to-be fibroblast-like synoviocytes. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - December 9, 2023 Category: Rheumatology Source Type: research

Comparative effectiveness and cost evaluation of Risankizumab and Adalimumab in the management of psoriasis: a real-world study in Saudi Arabia
Psoriasis, an immune-mediated chronic inflammatory disease primarily affecting skin and joints, has varying prevalence rates globally. It manifests in five types, with chronic plaque psoriasis being the most c... (Source: Cost Effectiveness and Resource Allocation)
Source: Cost Effectiveness and Resource Allocation - December 9, 2023 Category: Health Management Authors: Yazed AlRuthia, Almaha H. Alfakhri, Ibtisam Alharbi, Fadi Ali Alghamdi, Miteb A. Alanazi, Abdullah Abdulrahman Alrabiah, Anwar Abdulrazzag Alsouan, Abdulrahman Abdullah Alshaikh and Majed Ali Almasaoud Tags: Research Source Type: research

Is the Availability of Biosimilar Adalimumab Associated with Budget Savings? A Difference-in-Difference Analysis of 14 Countries
ConclusionThe availability of biosimilars was associated with a decrease in adalimumab expenditure without compromising the consumption of adalimumab. (Source: BioDrugs)
Source: BioDrugs - December 8, 2023 Category: Drugs & Pharmacology Source Type: research

Surgical induced necrotizing scleritis following intraocular lens replacement
ConclusionSurgery-induced necrotizing scleritis is a severe condition that compromise the ocular and visual integrity. Proper diagnosis, as well as early treatment is required to achieve remission, prevent relapses, and avoid structural complications. In refractory cases, anti-TNF- α immunotherapy associated with surgical tectonic graft interventions can achieve promising results. (Source: Journal of Ophthalmic Inflammation and Infection)
Source: Journal of Ophthalmic Inflammation and Infection - December 7, 2023 Category: Opthalmology Source Type: research

Cutaneous Naganishia albida (Cryptococcus albidus) infection: a case report and literature review
We describe a case of an immunocompetent older male with cutaneous cryptococcosis caused by Naganishia albida following skin trauma, and conduct a literature review in PubMed, Lilacs, and Embase. Only six previous similar reports were found. The seven cases (including ours) were widely distributed geographically (Brazil, the US, the UK, Hungary, South Korea, and Iran), all males, and their ages varied, ranging from 14 to 86 years. Four individuals had underlying skin diseases (Sezary Syndrome, psoriasis, and skin rash without etiology) plus potentially immunosuppressive underlying conditions (diabetes mellitus, kidney tran...
Source: Revista do Instituto de Medicina Tropical de Sao Paulo - December 6, 2023 Category: Tropical Medicine Authors: V ítor Falcão de Oliveira Alexandre Pereira Funari Mariane Taborda Adriana Satie Gon çalves Kono Magri Anna Sara Levin Marcello Mihailenko Chaves Magri Source Type: research